DiaSorin (OTCMKTS:DSRLF) Stock Rating Upgraded by Zacks Research

DiaSorin (OTCMKTS:DSRLF) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other analysts also recently issued reports on the stock. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. BNP Paribas Exane raised shares of DiaSorin to a “neutral” rating in a research note on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

DiaSorin Price Performance

Shares of OTCMKTS:DSRLF opened at $67.00 on Tuesday. The stock’s 50-day moving average price is $71.57 and its two-hundred day moving average price is $75.91. DiaSorin has a 12-month low of $66.50 and a 12-month high of $112.30.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.